Companies › Bristol-Myers Squibb
70 active drug programs in 1064 registered trials: 571 Phase 2, 336 Phase 1, 135 Phase 3, 22 Phase 4; Oncology, Immunology, Neurology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Trospium Chloride Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Schizophrenia; Bipolar-I Disorder With Mania or Mania With Mixed Features; Bipolar Disorder Type I With Mania or Mania With Mixed Features; Mania … | Nov 2026 |
| Deucravacitinib Tyrosine-protein kinase TYK2 negative allosteric modulator | TYK2 | Phase 4 | Systemic Lupus Erythematosus (SLE); Psoriatic Arthritis; Sjögren's Syndrome; Systemic Lupus Erythematosus … | Nov 2026 |
| Trospium Chloride (BMS-986510) Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Healthy Volunteers; Psychosis Associated With Alzheimer's Disease; Alzheimer Disease; Schizophrenia | Nov 2026 |
| Mavacamten (BMS-986427) Cardiac myosin inhibitor | MYH7, MYH6, MYH7B, MYL3, MYL2 | Phase 4 | Cardiomyopathy, Hypertrophic; Symptomatic Obstructive Hypertrophic Cardiomyopathy | Jun 2027 |
| Luspatercept (ACE-536) Transforming growth factor beta inhibitor | TGFB1, TGFB2, TGFB3 | Phase 4 | Anemia; Myelodysplastic Syndromes; Beta-thalassemia; CCUS Clonal Cytopenia of Undetermined Significance … | Jul 2027 |
| Ozanimod Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor 5 modulator | S1PR1, S1PR5 | Phase 4 | Relapsing Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative; Alzheimer Disease | Dec 2028 |
| Adagrasib GTPase KRas inhibitor | KRAS | Phase 3 | Metastatic Non Small Cell Lung Cancer; Advanced Colorectal Cancer; Carcinoma, Non-Small-Cell Lung; Advanced Cancer … | Nov 2026 |
| CC-92480 (BMS-986348, mezigdomide) Cereblon E3 ligase modulator (cereblon-binding protein that promotes IKZF1 and IKZF3 degra | CRBN | Phase 3 | Relapsed or Refractory Multiple Myeloma; Multiple Myeloma | Nov 2026 |
| Nivolumab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Urothelial Cancer; Melanoma; Renal Cell Carcinoma; Metastatic Colorectal Cancer … | Nov 2026 |
| Relatlimab Lymphocyte activation gene 3 protein inhibitor | LAG3 | Phase 3 | Non-small Cell Lung Cancer; Melanoma; Cancer; Urologic Neoplasms … | Dec 2026 |
| Ipilimumab Cytotoxic T-lymphocyte protein 4 inhibitor | CTLA4 | Phase 3 | Urothelial Cancer; Renal Cell Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer … | Feb 2027 |
| Repotrectinib Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | NTRK1, NTRK2, ROS1, NTRK3, CD74 | Phase 3 | Carcinoma, Non-Small-Cell Lung | Feb 2027 |
| Xanomeline Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM4, CHRM1 | Phase 3 | Alzheimer Disease; Alzheimer's Disease; Healthy Volunteers; SCHIZOPHRENIA 1 (Disorder) | Mar 2027 |
| Golcadomide (CC-99282, BMS-986369) Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader | CRBN, IKZF1, IKZF3 | Phase 3 | Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin … | Apr 2027 |
| BMS-986278 LOXL2 inhibitor | LOXL2 | Phase 3 | Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis | Jun 2027 |
| Abatacept T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor | CD86, CD80 | Phase 3 | Rheumatoid Arthritis; Myocarditis Acute; Polyarticular Course Juvenile Idiopathic Arthritis (JIA); Biphenotypic Acute Leukemia … | Sep 2027 |
| BMS-986365 Androgen receptor degrader (PROTAC) | – | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Sep 2027 |
| Luspatercept (ACE-536) Transforming growth factor beta inhibitor | TGFB1, TGFB2, TGFB3 | Phase 3 | Myelodysplastic Syndromes; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders; Beta-Thalassemia | Sep 2027 |
| Iberdomide CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma; Lymphoma, B-Cell; Newly Diagnosed Multiple Myeloma; Smoldering Plasma Cell Myeloma … | Nov 2027 |
| BMS-986393 (Arlocabtagene autoleucel, arlo-cel) | – | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM); Multiple Myeloma | Dec 2027 |
| BMS-986507 (Iza-bren, Izalontamab brengitecan) | – | Phase 3 | Non-Small Cell Lung Cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Urothelial Cancer … | Mar 2028 |
| Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Follicular Lymphoma | Apr 2028 |
| Pumitamig (BMS-986545, BNT327, PM8002) | – | Phase 3 | Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer (NSCLC); Solid Tumors; Locally Advanced Non-Small Cell Lung Cancer (NSCLC) … | Jul 2028 |
| Mezigdomide Cereblon E3 ubiquitin ligase modulator (CRBN modulator) | CRBN | Phase 3 | Relapsed or Refractory Multiple Myeloma | Jul 2029 |
| idecabtagene vicleucel Tumor necrosis factor receptor superfamily member 17 binding agent | TNFRSF17 | Phase 3 | Multiple Myeloma | Nov 2029 |
| Xanomeline (BMS-986519) Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM4, CHRM1 | Phase 3 | Schizophrenia | Mar 2030 |
| Belatacept T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor | CD86, CD80 | Phase 3 | Renal Allograft Recipients; Kidney Diseases; Chronic Kidney Failure; Heart Transplantation … | Dec 2032 |
| Navlimetostat (BMS-986504) Selective, MTA-cooperative PRMT5 inhibitor | PRMT5, MTAP | Phase 2 | Solid Tumors; Pancreatic Ductal Adenocarcinoma; Healthy Participants; Healthy Female Participants … | Nov 2026 |
| BMS-986435 | – | Phase 2 | Heart Failure; Healthy Volunteers | Dec 2026 |
| BMS-986446 Anti-microtubule-binding region (MTBR) tau monoclonal antibody | MAPT | Phase 2 | Alzheimer Disease, Early Onset; Alzheimer's Disease | Dec 2026 |
| Irafamdastat (BMS-986368, CC-97489) FAAH/MAGL inhibitor | FAAH, MAGL | Phase 2 | Multiple Sclerosis Spasticity; Agitation; Healthy Volunteers | Dec 2026 |
| BMS-986504 (MRTX1719) Selective MTA-cooperative inhibitor of PRMT5 | MTAP, PRMT5 | Phase 2 | Carcinoma, Non-Small-Cell Lung; Metastatic Non-small Cell Lung Cancer With MTAP Deletion; Advanced Solid Tumors; Advanced Solid Tumors With Homozygous MTAP Deletion … | Jan 2027 |
| CC-97540 CD19-targeted CAR T cells | CD19 | Phase 2 | Lupus Erythematosus, Systemic; Multiple Sclerosis; Systemic Lupus Erythematosus; Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Jul 2027 |
| Lisocabtagene Maraleucel B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Lymphoma | Jan 2028 |
| Azacitidine (BMS-986345) DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor | DNMT3A, DNMT1 | Phase 2 | Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Angioimmunoblastic T-cell Lymphoma (AITL) … | Jul 2028 |
| Daraxonrasib (RMC-6236) KRAS inhibitor | KRAS | Phase 2 | Solid Tumors | Aug 2028 |
| Imzokitug Anti-CCR8 monoclonal antibody | CCR8 | Phase 2 | Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Pancreatic Adenocarcinoma | Sep 2028 |
| Lisocabtagene Maraleucel (JCAR017) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Lymphoma, Non-Hodgkin | Sep 2031 |
| Gene-modified T cell therapy | – | Phase 2 | Neoplasms | May 2043 |
| BMS-986521 M4 muscarinic acetylcholine receptor antagonist | CHRM4 | Phase 1 | Healthy Volunteers | Nov 2026 |
| CC-122 (also: Avadomide, BMS-986381) Cereblon E3 ligase modulator | CRBN | Phase 1 | Non-Hodgkin Lymphoma | Nov 2026 |
| Fedratinib Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | FLT3, JAK2 | Phase 1 | Primary Myelofibrosis; Acute Myeloid Leukemia | Nov 2026 |
| Golcadomide (BMS-986369, CC-99282) Cereblon (CRBN) E3 ligase modulator | CRBN | Phase 1 | Kidney Failure, Chronic; Relapsed/Refractory Non-Hodgkin Lymphoma; Relapsed or Refractory T-cell Lymphomas | Dec 2026 |
| BMS-986470 P-selectin antagonist | – | Phase 1 | Anemia, Sickle Cell | Jan 2027 |
| BMS-986533 | – | Phase 1 | Healthy Volunteers | Jun 2027 |
| BMS-986454 | – | Phase 1 | Rheumatoid Arthritis | Jun 2027 |
| BMS-986484 | – | Phase 1 | Advanced Solid Tumors | Oct 2027 |
| BMS-986488 | – | Phase 1 | Advanced Malignant Tumors | Oct 2027 |
| BMS-986458 cereblon-dependent ligand-directed degrader of BCL6 | BCL6 | Phase 1 | Relapsed/Refractory Non-Hodgkin Lymphoma | Oct 2027 |
| Lisocabtagene Maraleucel (JCAR017) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 1 | Leukemia, Lymphocytic, Chronic, B-Cell; Recurrent Transformed Chronic Lymphocytic Leukemia; Lymphoma; Refractory Aggressive B-cell Lymphomas … | Nov 2027 |
| BMS-986517 | – | Phase 1 | Solid Tumours | Jul 2028 |
| Alnuctamab (BMS-986349, CC-93269, EM901) GPRC5D-targeting monoclonal antibody | GPRC5D | Phase 1 | Multiple Myeloma; Systemic Lupus Erythematosus | Aug 2028 |
| Iberdomide (BMS-986382) CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 1 | Multiple Myeloma | Aug 2028 |
| Mezigdomide (BMS-986348, CC-92480) Cereblon E3 ubiquitin ligase modulator | CRBN | Phase 1 | Multiple Myeloma; Extramedullary Disease in Multiple Myeloma; KMT2A-rearranged; Relapsed Refractory Multiple Myeloma (RRMM) … | Aug 2028 |
| Ezobresib (BMS-986158) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 1 | Multiple Myeloma; Myelofibrosis | Aug 2028 |
| BMS-986523 | – | Phase 1 | Advanced Solid Malignancies | Oct 2028 |
| BMS-986500 | – | Phase 1 | Advanced Solid Tumor | Dec 2028 |
| BMS-986463 | – | Phase 1 | High-grade Serous Ovarian Carcinoma (HGSOC) | Dec 2028 |
| BMS-986482 | – | Phase 1 | Advanced Solid Tumors | Jan 2029 |
| BMS-986515 CD19-targeted allogeneic CAR T cell therapy | CD19 | Phase 1 | Refractory Autoimmune Diseases | Mar 2029 |
| BMS-986525 | – | Phase 1 | Relapsed/Refractory Small Cell Lung Cancer | Apr 2029 |
| BMS-986460 | – | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Aug 2029 |
| BMS-986528 | – | Phase 1 | Arthritis, Rheumatoid | Oct 2029 |
| BMS-986490 anti-CEACAM5 antibody | CEACAM5 | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| BMS-986453 BCMA-directed CAR-T cell therapy | – | Phase 1 | Relapsed and/or Refractory Multiple Myeloma; Multiple Myeloma | May 2030 |
| BMS-986506 | – | Phase 1 | Renal Cell Carcinoma | May 2030 |
| BMS-986340 PRMT5 inhibitor | – | Phase 1 | Cervical Cancer | Aug 2031 |
| BMS-986449 | – | Phase 1 | Advanced Solid Tumors | – |
| Enasidenib (AG-221) Isocitrate dehydrogenase [NADP], mitochondrial inhibitor | IDH2 | Phase 1 | Leukemia, Myeloid, Acute; Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Myelodysplastic Syndromes … | – |
| Ivosidenib (AG-120) Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 1 | Leukemia, Myeloid, Acute | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02677922 | Ivosidenib (AG-120) | Phase 1 | Leukemia, Myeloid, Acute | Oncology | Aug 2018 |
| NCT02677922 | Enasidenib (AG-221) | Phase 1 | Leukemia, Myeloid, Acute | Oncology | Aug 2018 |
| NCT02632708 | Enasidenib (AG-221) | Phase 1 | Newly Diagnosed Acute Myeloid Leukemia (AML) | Hematology | Dec 2018 |
| NCT02656706 | Nivolumab | Phase 2 | Melanoma | Oncology | Mar 2019 |
| NCT02656706 | Ipilimumab | Phase 2 | Melanoma | Oncology | Mar 2019 |
| NCT02758717 | Nivolumab | Phase 2 | Ann Arbor Stage IB Hodgkin Lymphoma | Oncology | Aug 2019 |
| NCT03350126 | Nivolumab | Phase 2 | Metastatic Cancer Colorectal | Oncology | Jan 2020 |
| NCT03350126 | Ipilimumab | Phase 2 | Metastatic Cancer Colorectal | Oncology | Jan 2020 |
| NCT03452579 | Nivolumab | Phase 2 | Glioblastoma | Oncology | Dec 2020 |
| NCT03341936 | Nivolumab | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | Oncology | Jul 2021 |
| NCT03071406 | Nivolumab | Phase 2 | Merkel Cell Carcinoma | Oncology | Apr 2022 |
| NCT03071406 | Ipilimumab | Phase 2 | Merkel Cell Carcinoma | Oncology | Apr 2022 |
| NCT02743819 | Ipilimumab | Phase 2 | Melanoma | Oncology | Jun 2022 |
| NCT03241186 | Nivolumab | Phase 2 | Mucosal Melanoma | Oncology | Sep 2022 |
| NCT03241186 | Ipilimumab | Phase 2 | Mucosal Melanoma | Oncology | Sep 2022 |
| NCT04361162 | Nivolumab | Phase 2 | Pancreatic Cancer | Oncology | Oct 2022 |
| NCT04361162 | Ipilimumab | Phase 2 | Pancreatic Cancer | Oncology | Oct 2022 |
| NCT03161223 | Azacitidine (BMS-986345) | Phase 1 | Lymphoma, T-Cell | Oncology | Feb 2023 |
| NCT03038672 | Nivolumab | Phase 2 | ALK-Positive Large B-Cell Lymphoma | Oncology | May 2023 |
| NCT03377023 | Nivolumab | Phase 1 | Non Small Cell Lung Cancer | Oncology | Nov 2023 |
| NCT03377023 | Ipilimumab | Phase 1 | Non Small Cell Lung Cancer | Oncology | Nov 2023 |
| NCT03443856 | Nivolumab | Phase 2 | Gastric and Esophagogastric Junction Adenocarcinoma | Oncology | Dec 2023 |
| NCT03443856 | Ipilimumab | Phase 2 | Gastric and Esophagogastric Junction Adenocarcinoma | Oncology | Dec 2023 |
| NCT04575922 | Nivolumab | Phase 2 | Metastatic Microsatellite Stable Colorectal Cancer | Oncology | Dec 2023 |
| NCT04575922 | Ipilimumab | Phase 2 | Metastatic Microsatellite Stable Colorectal Cancer | Oncology | Dec 2023 |
| NCT05182957 | Azacitidine (BMS-986345) | Phase 2 | Relapsed/Refractory Peripheral T-cell Lymphoma | Oncology | Dec 2023 |
| NCT04685135 | Adagrasib | Phase 3 | Metastatic Non Small Cell Lung Cancer | Oncology | Dec 2023 |
| NCT03480334 | Nivolumab | Phase 2 | Classical Hodgkin Lymphoma | Oncology | May 2024 |
| NCT04195139 | Nivolumab | Phase 2 | Glioblastoma Multiforme | Oncology | Jun 2024 |
| NCT03036098 | Nivolumab | Phase 3 | Urothelial Cancer | Oncology | Aug 2024 |
| NCT03036098 | Ipilimumab | Phase 3 | Urothelial Cancer | Oncology | Aug 2024 |
| NCT05401786 | Ipilimumab | Phase 2 | Carcinoma, Non-Small-Cell Lung | Oncology | Nov 2024 |
| NCT02648997 | Nivolumab | Phase 2 | Meningiomas | Oncology | Dec 2024 |
| NCT02648997 | Ipilimumab | Phase 2 | Meningiomas | Oncology | Dec 2024 |
| NCT04003649 | Nivolumab | Phase 1 | Recurrent Glioblastoma | Oncology | Dec 2024 |
| NCT04003649 | Ipilimumab | Phase 1 | Recurrent Glioblastoma | Oncology | Dec 2024 |
| NCT05197426 | Azacitidine (BMS-986345) | Phase 2 | Acute Myeloid Leukemia | Oncology | Jan 2025 |
| NCT04905810 | Azacitidine (BMS-986345) | Phase 2 | Acute Myeloid Leukemia | Oncology | May 2025 |
| NCT05480384 | Nivolumab | Phase 2 | Esophageal Adenocarcinoma | Oncology | May 2025 |
| NCT02914405 | Nivolumab | Phase 1 | Neuroblastoma | Oncology | Jun 2025 |
| NCT04126070 | Nivolumab | Phase 2 | Hormone Sensitive Prostate Cancer | Oncology | Jul 2025 |
| NCT05567458 | Luspatercept (ACE-536) | Phase 2 | Beta-thalassemia | Hematology | Aug 2025 |
| NCT04203316 | Enasidenib (AG-221) | Phase 2 | Recurrent Acute Myeloid Leukemia | Oncology | Sep 2025 |
| NCT04006262 | Nivolumab | Phase 2 | Localized Oesogastric Adenocarcimona | Oncology | Oct 2025 |
| NCT04006262 | Ipilimumab | Phase 2 | Localized Oesogastric Adenocarcimona | Oncology | Oct 2025 |
| NCT05595447 | Nivolumab | Phase 2 | Hodgkin Lymphoma | Oncology | Oct 2025 |
| NCT05413018 | Azacitidine (BMS-986345) | Phase 2 | Leukemia, Myeloid, Acute | Oncology | Oct 2025 |
| NCT04803877 | Nivolumab | Phase 2 | Osteosarcoma | Oncology | Nov 2025 |
| NCT05833438 | Azacitidine (BMS-986345) | Phase 2 | Acute Myeloid Leukemia (AML) | Oncology | Nov 2025 |
| NCT03670056 | Nivolumab | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT05598853 | Nivolumab | Phase 1 | Leptomeningeal Metastasis | Oncology | Dec 2025 |
| NCT03670056 | Ipilimumab | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT05598853 | Ipilimumab | Phase 1 | Leptomeningeal Metastasis | Oncology | Dec 2025 |
| NCT05325099 | Azacitidine (BMS-986345) | Phase 1 | Acute Kidney Disease | Genitourinary | Dec 2025 |
| NCT04793958 | Adagrasib | Phase 3 | Advanced Colorectal Cancer | Oncology | Jan 2026 |
| NCT04184505 | Azacitidine (BMS-986345) | Phase 3 | High-risk MDS | Oncology | Mar 2026 |
| NCT05901974 | Azacitidine (BMS-986345) | Phase 2 | Acute Leukemia of Ambiguous Lineage | Oncology | Mar 2026 |
| NCT05732961 | Luspatercept (ACE-536) | Phase 2 | Myelodysplastic Syndromes | Hematology | Mar 2026 |
| NCT04295863 | Nivolumab | Phase 1 | Metastatic Cancer | Oncology | Apr 2026 |
| NCT04400539 | Nivolumab | Phase 2 | Mesotheliomas Pleural | Oncology | May 2026 |
The 60 nearest readouts of 1064 trials; the rest in the app.
Cash and short-term investments of $12.6bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.